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C-reactive protein  (CRP) 1 is  an  acute  phase  serum  protein  produced rapidly  in 
response to inflammatory stimuli. The binding and functional characteristics of CRP 
suggest that  it  may play a  role in  host defense against  infection. CRP has binding 
specificity  for  the  phosphocholine  (PC)  determinant  of cell  wall  C-polysaccharide 
(PnC)  from Streptococcus pneumoniae  (1, 2). The binding of CRP to PnC can lead to C 
activation in human serum by the classical pathway (3). We have found CRP binding 
and C  activation by intact  S.  pneumoniae  of several  different  serotypes  (unpublished 
observations). 
CRP  in  the  presence  of human  C  has  been  shown  to  opsonize  PnC-sensitized 
erythrocytes (E-PnC)  for phagocytosis by human monocytes (4)  and  mouse macro- 
phages (5). We have extended these studies by demonstrating opsonization of mouse 
E-PnC by CRP in a  mouse in vivo clearance model (6). Opsonization in this system 
resulted in increased splenic localization of E-PnC and required the presence of both 
CRP and mouse C. Despite these findings with E-PnC, the effectiveness of CRP as a 
bacterial  opsonin has  been  uncertain.  Earlier  in  vitro studies  of phagocytosis have 
been  conflicting  (7-9).  In  an  in  vivo  study,  an  association  was  reported  between 
elevated  levels  of CRP  and  increased  resistance  to  Staphylococcus  aureus  infection  in 
endotoxin-treated  mice  (10).  We  have  found an  enhanced  phagocytic response  by 
human neutrophils to CRP- and C-treated S. pneumoniae  type 27 that has capsular as 
well as cell wall PC determinants. 2 
Recently Briles et al.  (11)  reported that IgM antibody to PC can protect CBA/N 
mice against intravenous challenge with type 3 S. pneumoniae  (Pn3). Since CRP shares 
the  binding  specificity  and  opsonic  activity  of IgM  antibody  to  PC,  it  might  be 
expected to provide similar protection. We have found that pretreatment with CRP 
can  increase survival of mice infected with  Pn3 or type 4  S.  pneumoniae  (Pn4).  This 
effect was evident in normal BALB/c mice and in mice unable to produce antibody 
to PC because of neonatal tolerance induction. This study provides direct evidence of 
the effectiveness of CRP in host defense against pneumococcal infection. 
* Supported by research grant AI-12870  from the National Institutes of Health, Bethesda, Md. 
Thomas J. Coogan, Sr., Chair in Immunology  established by Marjorie Lindheimer Everett. 
1  Abbreviations used in thispaper: otT15, A-HeJ antiserum against HOPC-8  myeloma  protein; CFU, colony- 
forming units; CRP, C-reactive protein; E-PnC, erythrocytes  coated with pneumococcal  C-polysaccharide; 
PC,  phosphocholine; Pn3, Pn4, serotypes 3 and  4 of Streptococcus pneumoniae; PnC, pneumococcal C- 
polysaccharide. 
2  Edwards, K., H. Gewurz, T. F. Lint, and C. Mold. A role for C-reactive protein in the complement- 
mediated opsonization of type 27 Streptococcus  pneumoniae. Manuscript in preparation. 
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Materials and Methods 
Animals.  BALB/c mice were  purchased from Cumberland View Farms (Clinton, Tenn.). 
Newborn BALB/c mice were obtained from females that were pregnant when received. A/HeJ 
mice were purchased from The Jackson Laboratory (Bar Harbor, Maine). 
Bacteria.  Pn4 and the nonencapsulated  strain R36a were obtained from the American Type 
Cell Culture Collection (Rockville, Md.). Pn3 was a clinical isolate from the Vanderbilt Vaccine 
Clinic provided by Dr. Kathryn Edwards (Vanderbih University, Nashville, Tenn.). Bacteria 
were maintained on sheep blood agar (BBL Microbiology Systems,  Becton, Dickinson & Co., 
Cockeysville,  Md.). Pn3 and Pn4 were passaged through mice before use in these studies. For 
inoculation  of mice, log phase cultures of Pn3 or Pn4 in Todd-Hewitt broth (Difco Laboratories, 
Detroit, Mich.) were collected by centrifugation, washed, and resuspended in saline. 
Antigens  and Antisera.  PnC was isolated from R36a by the method of Liu and Gotschlich 
(12). The PC-binding myeloma protein, HOPC-8, was prepared from ascites in tumor-bearing 
BALB/c mice and purified by methods published previously (13). Antibody to the T 15 idiotype 
of HOPC-8 (aTI5) was raised by immunizing  A/HeJ mice with HOPC-8 as described (14). 
Neonatal  Suppression.  BALB/c mice were injected intraperitonealiy within 2 d  after birth 
with either 0.I ml of 10 p.g/ml PnC or 0.1 ml of aTI5 serum. Mice treated in these ways have 
been shown to exhibit tolerance to PC antigens as adults (14). Neonatally suppressed mice were 
used at 8-12 wk of age. 
Measurement of Antibody  to PnC.  Antibody titers to PnC in normal and suppressed mice were 
measured by hemagglutination of sheep E coated with PnC (14). 
CRP  Human CRP was purified from pleural and peritoneal fluids as previously described 
(15). 
Protection of Mice by CRP.  Mice were injected intravenously  with 150 or 200 #g of CRP in 0.1 
ml. After 30 min mice were injected intravenously  with 0. I ml bacteria. The number of viable 
bacteria injected was determined from plate counts of each inoculum. Results were analyzed 
by the X  2 test. 
Results 
Tolerance to PC antigens was induced by injecting mice as neonates with either 
PnC  or  aT15.  Antibody titers  to  PnC  were  determined  in  serum  samples  from 
suppressed and control mice at 8-12 wk of age (Table I). Titers were also determined 
in surviving mice on day 3  after intravenous injection with 6  ×  104 colony-forming 
units (CFU) of Pn3. The effectiveness of the tolerance induction was shown by the 
low  titers of antibody in suppressed mice  (highest  titer  24)  compared with control 
mice  (titers  ranging from  27  to  21°).  Neonatal suppression of mice with  PnC  also 
increased their susceptibility to Pn3 infection, decreasing the LDso from 5 ×  104 CFU 
in normal mice to <5 ×  10  a CFU in PnC-suppressed mice. 
Mice suppressed by aT15 treatment were injected with 200 #g CRP and challenged 
with 5  ×  104 or  1 ×  105 CFU Pn3 (Fig.  1). For the lower inoculum, CRP treatment 
TABLE I 
Antibody  to PnC in Normal and NeonataUy Suppressed BALB/c Mice 
Neonatal treatment* 
Antibody  to PnC (logz serum titer) 
Preinfection:~  Postinfection:~ 
n§  mean  range  n  mean  range 
Saline  5  9.0  9-9 
None  5  9.2  9-10  9  7.8  7-9 
PnC  24  1.5  0-3  11  2.6  2-4 
aT15  22  0.5  0-3  9  2.6  2-4 
* Mice were injected  within 2 d after birth with 0.1 ml saline, 10 #g/ml PnC,  or aT15 serum i.p. 
:~ Serum antibody  was measured in 8 12 wk-old mice and in surviving  mice 3 d after injection  of Pn3. 
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Fxo.  1.  Effect of CRP  treatment on survival of suppressed mice infected with Pn3.  Mice treated 
as neonates with aT15 were treated with 200 ~g CRP  in 0.1  ml or 0.1 ml saline i.v. 30 min before 
intravenous injection of 5  ×  104 CFU (panel A) or 105 CFU (panel B) of Pn3. Number of surviving 
mice are shown in parentheses. 
TAaI.E  II 
Effect of CRP Treatment on Survival of Normal BALB/c Mice 
Infected with Pn3 
Inoculum (CFU Pn3)  Treatment*  n*  Percent alive~ 
2 ×  104  CRP  5  100 
2 ×  104  Saline  5  60 
8 ×  104  CRP  8  88 
8 ×  104  Saline  8  25 
5 ×  105  CRP  5  20 
5 x  105  Saline  5  0 
* Mice were injected with 200 #g CRP in 0.I ml or with 0.1 ml saline i.v. 30 rain before 
intravenous injection of Pn3. 
Number of mice tested. 
§ Survival 10 d postinfection. Deaths occurred between 2 and 7 d after infection. 
increased  survival from 20  to  100%  (P <  0.01).  CRP  was also protective with  the 
higher inoculum, increasing survival from 0  to 50%  (P <  0.05).  Similar results were 
observed with PnC-suppressed mice (not shown). 
Next we tested the effect of CRP in normal mice challenged with Pn3  (Table II). 
Mice pretreated with CRP showed an increase in the percent surviving at every dose 
tested. The difference in mortality between CRP-treated and control mice was highly 
significant  (P <  0.005)  at an inoculum  of 8  ×  104 CFU. CRP treatment of normal 
mice increased the LDs0 from 4 ×  104 to 2 ×  105 CFU Pn3. 
CRP is not known to react with the type-specific capsular polysaccharide of Pn3 
(16). Therefore we felt that its ability to protect mice against Pn3 infection was related 
to its binding to PnC in the cell wall. To test this hypothesis, we assessed the ability 
of CRP to protect mice from infection with  Pn4  (Fig.  2).  The Pn4 strain used was 
highly virulent with an LDso of ~ 102 CFU in normal mice. CRP increased survival 
of mice infected with  10  s CFU Pn4 from 33 to 82% (P <  0.025). 
Discussion 
The  experiments  presented  here  define  a  mouse  model  in  which  human  CRP 
provides protection against pneumococcal infection.  Previous studies on the opsonic 1706  MOLD  ET  AL.  BRIEF  DEFINITIVE REPORT 
'-.4 
I00" 
90- 
80- 
?'0- 
60- 
50- 
40- 
30- 
20- 
I0- 
NORMAL, I03 Pn4 
SALINE 14/12 ) 
OAg$ 
FIG.  2.  Effect  of CRP treatment on survival of normal mice injected with Pn4. Mice were treated 
with 150 #g CRP in 0.1 ml or 0.1 ml saline i.v. 30 min before intravenous injection of 10  a CFU of 
Pn4. Number of surviving mice are shown in parentheses. 
properties of CRP have shown species compatibility between human CRP and mouse 
macrophages  (5), and between human CRP and mouse C  (6).  We therefore felt that 
the  mouse represented  a  reasonable  model  with  which  to study  the  effectiveness  of 
CRP as a  bacterial opsonin. 
In BALB/c mice, CRP is a  trace serum protein that does not elevate beyond 2/~g/ 
ml  (17).  These  mice have  high  titers  of antibody  to PC  before immunization.  This 
antibody is predominantly of the T15 idiotype and may be suppressed by injection of 
aT15 or PnC early in life (14). Thus, neonatally suppressed  BALB/c mice lack both 
CRP and antibody to PC.  We have shown here that such mice are more susceptible 
to infection with Pn3 than normal BALB/c mice. This supports the findings of Briles 
et al.  (11) who reported a protective role for antibody to PC in CBA/N mice infected 
with Pn3. 
CRP  injected  intravenously  to attain  levels similar  to those  in acute phase serum 
protected suppressed  mice against  Pn3 infection.  Such mice lacked antibody to PnC 
both before and after infection whether or not they were treated with CRP. Injection 
of CRP  was  effective even  in  the  presence  of natural  antibody  to  PnC,  because  it 
increased survival of normal mice infected with Pn3. CRP also protected mice against 
Pn4  infection,  reflecting  its  reactivity  with  the  group-specific polysaccharide.  Since 
CRP  lacks reactivity with  the capsular polysaccharides of Pn3 and  Pn4  (16,  18),  its 
protective ability is apparently related  to its PnC specificity. 
In previous experiments  (6) CRP has been found to increase the splenic localization 
of E-PnC  in  mice.  Since  the spleen  has been shown to be particularly  important  in 
protection against  pneumococcal infections  (19,  20), alteration  of clearance patterns 
of S.  pneumoniae in  the  presence  of CRP  may  be  responsible  for  protection  from 
lethality. 
These experiments demonstrate a  role for CRP in host defense against pneumococ- 
cal  infection.  The  early  production  of CRP  in  response  to  infection  may  provide 
group-specific  protection  against  S.  pneumoniae in  the  presence  or  absence  of an 
antibody response. MOLD ET AL.  BRIEF  DEFINITIVE REPORT  1707 
Summary 
C-reactive protein  (CRP)  has several properties  that suggest  that  it  may function 
as a  bacterial opsonin. CRP shows binding reactivity with pneumococcal C-polysac- 
charide,  the cell  wall carbohydrate of Streptococcus  pneumoniae.  In this  study we have 
demonstrated  protection of mice against  serotypes 3  and 4 of S. pneumoniae  infection 
by a  single  prior  injection  of CRP.  This  effect  was  seen  both  in  mice  that  lacked 
antibody to phosphocholine and in normal mice. Thus the opsonic properties of CRP 
previously described may be related  to protection against pneumococcal infection. 
Received  for publication 6 August  1981. 
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